Loading
institutionsInstitution
Scottish Medicines Consortium
Scotland's health technology assessment body, which advises NHS Scotland on new medicines and applies a more flexible approach for end-of-life and orphan cancer drugs.
Also called: SMC
Overview
Established in 2001, the Scottish Medicines Consortium advises NHS Scotland on the clinical and cost-effectiveness of all newly licensed medicines, working separately from NICE. Its Patient and Clinician Engagement process, introduced in 2014, gives additional weight to patient and clinician evidence for end-of-life and very rare conditions, and its ultra-orphan pathway allows access while evidence is collected, so some cancer drugs are available in Scotland before or without a NICE recommendation. The SMC is part of Healthcare Improvement Scotland and works with the MHRA and NICE on the Innovative Licensing and Access Pathway.
Location
Glasgow, GB
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#447 · 10 points (0 Newsweek + 0 NCI + 10 from 5 linked objects) · ranking
- Health technology assessment for NHS Scotland
- Patient and Clinician Engagement (PACE) process
- Ultra-orphan pathway
- Innovative Licensing and Access Pathway partner
Similar pages
- TermInnovative Medicines Fund (England)
Shares NICE technology appraisal methods (2022), National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionPharmaceutical Benefits Advisory Committee
Shares ISPOR (The Professional Society for Health Economics and Outcomes Research), National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- TermCancer Drugs Fund (England)
Shares NICE technology appraisal methods (2022), ILAP (Innovative Licensing and Access Pathway), National Institute for Health and Care Excellence, Real-world evidence.
- CollectionNICE cancer guidance and technology appraisals (UK)
Shares NICE technology appraisal methods (2022), ILAP (Innovative Licensing and Access Pathway), National Institute for Health and Care Excellence.
- IdeaCopy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data
Shares National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionHaute Autorité de Santé
Shares ISPOR (The Professional Society for Health Economics and Outcomes Research), National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionBundesinstitut für Arzneimittel und Medizinprodukte
Shares Medicines and Healthcare products Regulatory Agency, National Institute for Health and Care Excellence, Prices and value.
- TermMedicines and Medical Devices Act 2021
Shares ILAP (Innovative Licensing and Access Pathway), Medicines and Healthcare products Regulatory Agency.